Heron Therapeutics: SABCS 2015 (Heron Therapeutics) - Dec 20, 2015 - "APF530 is the first and only 5-HT3 receptor antagonist to demonstrate superiority over another as part of the guideline-recommended regimen in a 3-drug versus 3-drug phase 3 efficacy trial"; "In patients receiving AC-based HEC numerical trends favored APF530 over ondansetron in CR in delayed-phase CINV, although statistical significance was not reached"; "These findings suggest concordance with the significantly superior control of delayed-phase CINV observed with APF530 versus ondansetron in the overall study population"; "Prevention of CINV in patients receiving AC-based HEC continues to be a challenge; these promising preliminary findings suggest a benefit of APF530 in this population and warrant further investigation"
P3 data • Oncology
|